Unlike A/I degraders, including thalidomide and pomalidomide, lenalidomide has a CK1α-degrading effect (5, 9) and has been used to treat several hematopoietic malignancies, including DLBCL, follicular lymphoma (FL), MCL, and 5q deletion myelodysplastic syndrome [del(5q) MDS] (4, 5, 9). This evidence concerns the gene CSNK1A1 and diffuse large B-cell lymphoma.